Paul A Mahon sold $4.1M of UTHR
EVP & GENERAL COUNSEL at UNITED THERAPEUTICS Corp. 8,300 shares at an average of $497.54, traded Sep 17, 2026, filed Sep 18, 2026.
Score components
- +15RoleOfficer
- +25Trade size$4.1M at market
- +5Share of holdings soldSold 16% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231589-26-000020, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | MOption exercise Common Stock10b5-1 | +8,300 | $146.03 | $1.2M | 53,472 | 24 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stock10b5-1 | -1,579 | $495.97 | $783k | 51,893 | 24 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stock10b5-1 | -2,873 | $496.58 | $1.4M | 49,020 | 24 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stock10b5-1 | -1,400 | $497.54 | $697k | 47,620 | 24 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stock10b5-1 | -843 | $498.74 | $420k | 46,777 | 24 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stock10b5-1 | -1,160 | $499.75 | $580k | 45,617 | 24 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stock10b5-1 | -125 | $500.80 | $63k | 45,492 | 24 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stock10b5-1 | -320 | $501.58 | $161k | 45,172 | 24 d ago |
| Sep 17, 2026 | MOption exercise Stock Optionderivative10b5-1 | -8,300 | $0.00 | $0 | 47,540 | 24 d ago |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.